Baricitinib (4 mg), a contemporary, selective, and reversible inhibitor of Janus Kinases (JAK1 and JAK2), is available as a prescription oral preparation under the brand name Barigen 4 mg. The product functions as a bioequivalent and reasonably priced generic version of the groundbreaking medication Olumiant® (Eli Lilly & Co.) and is produced by General Pharmaceuticals Ltd. under rigorous control of Current Good Manufacturing Practices (cGMP).
Barigen 4 mg is authorized for the treatment of patients with moderate and severe active rheumatoid arthritis (RA) who do not respond well to conventional disease-modifying anti-rheumatic medications (DMARDs) and biological TNF inhibitors, as well as severe alopecia areata, a condition marked by extensive hair loss of the scalp, eyebrows, and lashes.
Additionally, certain hospitalized adult patients with severe COVID-19 who require additional oxygen can utilize baricitinib. A single daily oral pill called Barigen 4 mg is a synthetic DMARD (tsDMARD) that inhibits cytokine-induced inflammatory pathways from within the cells.
| Attribute | Specification |
|---|---|
| Brand Name | Barigen |
| Generic Name | Baricitinib (INN) |
| Dosage Strength | 4 mg per tablet (also produced in 2 mg strength) |
| Dosage Form | Oral film-coated tablet |
| Therapeutic Class | Janus Kinase (JAK1/JAK2) Inhibitor; Targeted Synthetic DMARD (tsDMARD) |
| ATC Code | L04AA37 / L04AF02 (Selective Immunosuppressants) |
| Manufacturer | General Pharmaceuticals Ltd. (Dhaka / Gazipur, Bangladesh) |
| Innovator Reference Brand | Olumiant® (Eli Lilly and Company / Incyte Corporation) |
| Standard Packaging | Box containing 30 tablets (3 blister strips of 10 tablets each) with leaflet |
| Regulatory Status | Approved by DGDA (Bangladesh); manufactured for domestic use and export |
| Prescription Status | Prescription Only Medicine (Rx) |
| Route of Administration | Oral (Systemic) |
| Storage Temperature | Store below 30°C (86°F); protect from moisture, light, and heat |
Bangladesh-based General Pharmaceuticals Limited (GPL) is a pharmaceutical company that specializes in creating and manufacturing final pharmaceutical products. Since its founding in the 1980s, the company has created a wide range of medications for both home and foreign markets.
Head Office: General Pharmaceuticals Limited. Sara Aftab Tower, 29 Ring Road, Holdings No. 6/1/A, Shyamoli, Adabor, Dhaka-1207.
Holdings no. 6/1/A, 29 Ring Road, Sara Aftab Tower, Adabor Main Rd, Dhaka 1207, Bangladesh
The firm creates medications in a variety of dosage formats and therapeutic areas. Tablets, capsules, oral liquids, ophthalmic goods, sterile products, injectables, large-volume parenterals, and other pharmaceutical formulations can all be produced at its facilities.
General Pharmaceuticals Ltd. produces the baricitinib product known as Barigen 4 mg.
Because multiple companies may develop goods with the same active component, manufacturer information is crucial for validating a medication.
Before using a product, patients and medical professionals should confirm its name, strength, manufacturer, batch information, and any relevant registration details.
Barigen 4 mg is a systemic immunomodulator used to treat inflammatory and autoimmune illnesses. The immune system aids in defending the body against infection by pathogens like bacteria and viruses in healthy individuals. Immune signaling dysregulation causes the body’s immune system to get confused and attack its own tissues as if they were dangerous, which leads to autoimmune diseases.
The pharmacological substance utilized in Barigen is called baricitinib. Baricitinib selectively inhibits certain cell enzymes, so controlling inflammation without changing the physiology of other bodily systems, in contrast to other immunosuppressive medications that nonspecifically suppress a variety of bodily systems.
Barigen 4 mg provides the same active chemistry, molecular structure (C₁₆H₁₇N₇O₂S), dose strength, and drug release characteristics as the international standard product Olumiant®. By sourcing highly pure active pharmaceutical ingredients (APIs) and adhering to rigorous bioavailability and dissolution testing, Varigen provides patients around the world with an affordable and accessible treatment route for chronic autoimmune diseases without compromising therapeutic efficacy or drug safety.
To grasp the functioning of Barigen 4 mg, it’s beneficial to analyze the intracellular communication routes of the human immune system.
Barigen 4 mg (Baricitinib) is clinically validated for specific, medically diagnosed immune-mediated diseases. It is essential to distinguish between approved indications and unverified conditions.
Alopecia areata is an autoimmune condition characterized by patchy or total hair loss on the scalp, face, and body. Barigen 4 mg is indicated for
Severe alopecia areata in adults, typically defined as a baseline Severity of Alopecia Tool (SALT) score of 50 or greater (indicating 50\% or more scalp hair loss, including alopecia totalis and alopecia universalis).
Barigen 4 mg is indicated for the treatment of moderate-to-severe active rheumatoid arthritis in adult patients who have had an inadequate clinical response or intolerance to one or more disease-modifying antirheumatic drugs (such as methotrexate, leflunomide, or sulfasalazine) or biologic TNF antagonists (such as adalimumab or etanercept).
During the global SARS-CoV-2 pandemic, baricitinib emerged as a critical therapeutic agent for hospitalized adult patients suffering from severe viral pneumonia requiring supplemental oxygen, high-flow oxygen, non-invasive ventilation, or mechanical ventilation.
Doctors in the European Union, the UK, and a few other places prescribe baricitinib for adults with moderate-to-severe eczema who need systemic treatment. In the BREEZE-AD1 and BREEZE-AD2 clinical trials, patients taking baricitinib once a day noticed their itching easing up within just 48 hours. Over the next 16 weeks, their skin cleared up too.
Barigen 4 mg must be taken exactly as prescribed by your physician. Dosage schedules should never be adjusted without medical consultation. Individual dosing depends on the medical indication, baseline kidney and liver function, patient age, and concurrent medications.
Because baricitinib is cleared predominantly by the kidneys (≈ 75 % excreted via renal elimination), estimating renal function via the estimated Glomerular Filtration Rate (eGFR) is mandatory before treatment initiation:
eGFR ≥ 60 mL/min/1.73 m² (Normal to Mild Impairment): No dosage adjustment needed.
eGFR 30 to <60 mL/min/1.73 m2 (Moderate Impairment): The dose must be halved. Patients who would otherwise receive 4 mg once daily must receive 2 mg once daily. Patients on a 2 mg daily regimen must reduce to 1 mg once daily.
eGFR <30 mL/min/1.73 m² (Severe Impairment / ESRD / Dialysis): Barigen is not recommended for rheumatoid arthritis or alopecia areata due to insufficient safety data and elevated drug accumulation.
Like all systemic medications affecting the immune system, Barigen 4 mg can cause side effects. Most are mild to moderate and manageable, but patients must remain vigilant for signs of serious complications.
These side effects occur in 1% to 10% of patients and typically subside as the body adapts to therapy:
If you experience any of the following symptoms, stop taking Barigen and seek emergency medical care immediately:
Baricitinib belongs to the Janus Kinase (JAK) inhibitor class. Regulatory authorities including the US FDA and the European Medicines Agency (EMA) have established class-wide Boxed Warnings for JAK inhibitors when prescribed for chronic inflammatory conditions.
Because Barigen 4 mg dampens specific immune pathways, patients have a higher risk of developing serious bacterial, mycobacterial, fungal, and viral infections that may lead to hospitalization.
In large post-marketing safety studies of another JAK inhibitor (tofacitinib) in patients aged 50 and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, major adverse cardiovascular events (MACE) (such as myocardial infarction and stroke), and thrombosis (deep vein thrombosis and pulmonary embolism) were observed compared to TNF blockers.
Lymphomas, non-melanoma skin cancers (NMSC), and other solid-organ malignancies have been reported in patients treated with JAK inhibitors. Periodic dermatological skin examinations are recommended for patients at elevated risk for skin cancer.
Safe long-term therapy requires baseline and periodic blood testing. The recommended monitoring schedule includes:
| Laboratory Test | Baseline (Pre-Treatment) | Week 12 Post-Initiation | Every 3 to 6 Months Thereafter |
|---|---|---|---|
| Complete Blood Count (CBC) | Mandatory | Mandatory | Routine monitoring |
| Absolute Neutrophil Count (ANC) | Do not start if | Pause if | Routine monitoring |
| Absolute Lymphocyte Count (ALC) | Do not start if < | Pause if | Routine monitoring |
| Hemoglobin (Hb) | Do not start if | Pause if | Routine monitoring |
| Renal Function (Serum Creatinine, eGFR) | Mandatory | Routine check | Routine check (dose adjustment if eGFR <60) |
| Liver Transaminases (ALT, AST) | Mandatory | Routine check | Pause if ALT/AST >5×times ULN |
| Fasting Lipid Profile (LDL, HDL, Triglycerides) | Mandatory | Mandatory | Periodic management as clinically indicated |
| Latent TB & Viral Hepatitis Screen | Mandatory | As clinically indicated | As clinically indicated |
Inform your prescribing doctor and dispensing pharmacist of all prescription medications, over-the-counter drugs, vitamins, and herbal supplements you take.
The originator/reference medicine associated with baricitinib is Olumiant, a branded medicine containing the active ingredient baricitinib. Baricitinib was developed through research involving Incyte Corporation, with Eli Lilly and Company collaborating in its development and commercialization. In the European Union, Olumiant received marketing authorization in February 2017, and the current EU marketing authorization holder is Eli Lilly Nederland B.V.
Olumiant contains the same active pharmaceutical ingredient, baricitinib, that is used in Barigen 4 mg. However, Barigen is a separate product manufactured by General Pharmaceuticals Ltd. A generic or branded-generic product should not be described as being manufactured by the originator company unless that company is actually responsible for manufacturing the specific product. Product manufacturer, registration status, formulation, packaging, and availability may differ between countries.
Olumiant is the branded medicine containing baricitinib that serves as an important reference product for baricitinib therapy. The European Medicines Agency identifies Olumiant as containing baricitinib and lists Eli Lilly Nederland B.V. as its marketing authorization holder in the European Union.
Olumiant was initially authorized in the EU for adults with moderate-to-severe active rheumatoid arthritis who had an inadequate response to, or could not tolerate, certain disease-modifying antirheumatic drugs. Its European authorization has subsequently included additional indications.
The existence of an originator product does not mean that every baricitinib product has identical regulatory status in every country. Patients should check the authorization applicable to the product and country concerned.
The approved indications for baricitinib differ by jurisdiction.
Baricitinib is authorized in certain jurisdictions for adults with moderate-to-severe active rheumatoid arthritis when previous disease-modifying antirheumatic drug treatment has not produced an adequate response or cannot be tolerated. In the EU, Olumiant may be used alone or together with methotrexate in appropriately selected patients.
Baricitinib is authorized in the EU for moderate-to-severe atopic dermatitis in adults and pediatric patients from 2 years of age who are candidates for systemic therapy. The exact age requirements and treatment criteria depend on the local authorization.
Baricitinib is also used for severe alopecia areata in certain patients. In the EU, the authorized indication includes adults and adolescents from 12 years of age with severe alopecia areata.
Current EU authorization includes baricitinib for selected patients aged 2 years and older with active juvenile idiopathic arthritis who have had an inadequate response to, or intolerance of, specified previous disease-modifying antirheumatic treatments. The authorization covers specified forms of juvenile idiopathic arthritis.
Baricitinib has also been authorized in the United States for certain hospitalized adults with COVID-19 who require specified levels of respiratory support. COVID-19 authorization should not be assumed to apply in every country. Regulatory status and treatment recommendations vary by jurisdiction.
Baricitinib affects immune-system signaling and can increase the risk of certain adverse effects.
Important safety considerations include:
JAK inhibitors have important safety warnings, and treatment decisions should take individual risk factors into account. Patients should contact their healthcare professional promptly if they develop symptoms suggesting a serious infection or another significant adverse reaction.
Barigen 4 mg and Olumiant contain the same active pharmaceutical ingredient, baricitinib.
The key difference is the product and manufacturer.
| Feature | Barigen 4 mg | Olumiant |
|---|---|---|
| Active ingredient | Baricitinib | Baricitinib |
| Strength discussed | 4 mg | Available in authorized strengths/formulations depending on market |
| Product type | Baricitinib product | Reference/originator branded product |
| Manufacturer/company | General Pharmaceuticals Ltd. | Eli Lilly / applicable marketing authorization holder |
| Administration | Oral | Oral |
| Drug class | JAK inhibitor | JAK inhibitor |
Product authorization, formulation, excipients, packaging, and availability can vary between markets.
Understanding the originator product can help patients distinguish between the active pharmaceutical ingredient and individual branded products.
Baricitinib is the active ingredient. Olumiant is the established branded product containing baricitinib. Barigen 4 mg is a separate baricitinib product containing 4 mg of the active ingredient.
The manufacturer of a particular product should always be verified from its packaging and official regulatory documentation.
Scan the QR code printed on the product box. The QR code will take you to the official General Pharmaceuticals product verification page, where you can complete the verification process.
The QR code will direct you to the General Pharmaceuticals Ltd. E-Verification page, where you can complete the product verification process.
After completing the verification, check the result carefully to confirm whether the product is genuine.
If the verification indicates that the product is fake or unauthorized, do not use it. Report the suspected counterfeit product and take appropriate legal action against the supplier through the Directorate General of Drug Administration (DGDA), World.
Always purchase medicines from licensed pharmacies or authorized suppliers and verify the product before use.
For reliable information about baricitinib and Olumiant, consult the applicable national medicines regulator and official product information. The European Medicines Agency identifies Olumiant as a medicine containing baricitinib and records its EU marketing authorization from 13 February 2017. Regulatory approvals, indications, warnings and age restrictions can change over time. Always use the current product information applicable to your country.
The information provided on Barigen.com is for general educational and informational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment.
Baricitinib is a prescription medicine that can cause serious adverse effects and may not be appropriate for everyone. Treatment decisions should be made by a qualified healthcare professional after considering the patient’s medical history, current medicines, laboratory results, and individual risk factors. Do not start, stop, or change Barigen 4 mg treatment without professional medical advice. Always refer to the official prescribing information and regulatory requirements applicable in your country.
Yes, they’re basically the same when it comes to the active ingredient and how they work. Barigen 4 mg is a generic version of Olumiant®, both containing 4 mg of baricitinib. They both block the JAK1 and JAK2 enzymes in your body. The main difference is cost Barigen, made by General Pharmaceuticals Ltd. under cGMP standards, offers a more affordable option.
Hair regrowth doesn’t happen overnight. In most clinical trials, the first signs, like soft, tiny colorless hairs, start to pop up around 8 to 12 weeks in. More noticeable scalp coverage, plus eyebrow and eyelash growth, usually shows up by weeks 24 to 36. For the fullest results, expect anywhere from 36 to 52 weeks of taking Barigen every day.
Alopecia areata doesn’t just go away; it’s a lifelong autoimmune problem. Baricitinib helps by stopping your immune system from attacking hair follicles, but it doesn’t fix the root cause. So if you quit taking it, the inflammation often comes back, and most people start shedding the regrown hair within 2 to 6 months. For many, long-term maintenance under a doctor’s care is the way to keep results.
No, Barigen 4 mg is only meant for autoimmune alopecia areata. It doesn’t work for male or female pattern baldness, which happens because of DHT sensitivity, not immune attack. Using a JAK inhibitor for pattern hair loss won’t help and just puts you at risk for side effects you don’t need.
No, you can’t. Barigen 4 mg is a powerful drug that can cause serious infections, blood clots, and issues with your blood work. Real pharmacies will always need a prescription from a doctor. If a website sells you baricitinib without a prescription, it’s not safe or legal; don’t risk it.
Baricitinib can affect your bone marrow, liver, and blood fats, so you need regular blood tests to make sure everything’s still normal. Doctors check for TB and viral hepatitis before you start. After that, expect check-ins at week 12 and every few months to make sure your blood counts, kidney and liver health, and cholesterol are all in line.
It depends on how well your kidneys work. Baricitinib leaves your body mostly through your kidneys. If your kidney function (eGFR) is between 30 and 59 mL/min, your doctor will cut your dose in half, so 2 mg instead of 4 mg. If your eGFR drops below 30, Barigen isn’t recommended at all.
If you get sick, like with a fever over 38°C (100.4°F), a bad cough, chills, or trouble peeing, let your doctor know right away. They may tell you to stop taking Barigen for a while until you’re better, because taking an immunosuppressant while you have an infection can make things worse.
For Spanish speakers, “baricitinib 4 mg para que sirve” means “what is baricitinib 4 mg used for?” Doctors use baricitinib 4 mg to treat serious alopecia areata, certain cases of moderate-to-severe rheumatoid arthritis when other treatments don’t work, and severe COVID-19 in hospitalized patients who need oxygen.
